WASHINGTON — A tiny eye drug company is about to walk away from Congress with a great big win: an extra two years of charging Medicare higher prices for its cataract surgery drug.

Tucked into some of the final pages of the sprawling, 2,232-page spending package congressional leaders unveiled late Wednesday are five pages detailing a complicated policy that represents a major win for Omeros, the Washington state-based company behind the cataract surgery drug Omidria. In fact, the language is painstakingly worded to ensure the policy affects Omeros and its product and almost no other drug companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • adam, do you ever mention that omidria is safer than any other alternative ? doctors and surgical centers, teaching hospitals prefer omidria over the unsafe practice of mixing ? safer enviornment for the patient ? your a real clown with an obvious vendetta against omeros.

  • Hey Adam, I thought you said Omero’s would never get pass-through. It’s amazing, you’ve had a personal vendetta against the Doctor and Omero’s, you’ve been paid to write lies, and help hedge funds short this stock time & time again. You are the type of person that makes the stock market an uneven playing field for the average retail investor (or anybody for that matter). No wonder you have been fired from so many places of employment, been investigated, and been in litigation because of your antics. It’s just a matter of time Mr. Adam!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy